Mark J. Murray Net Worth

The estimated Net Worth of Mark J. Murray is at least $1.56 Millón dollars as of 28 November 2018. Mark Murray owns over 25,000 units of Arbutus Biopharma Corp stock worth over $1,556,766 and over the last 9 years Mark sold ABUS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Murray ABUS stock SEC Form 4 insiders trading

Mark has made over 2 trades of the Arbutus Biopharma Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently Mark exercised 25,000 units of ABUS stock worth $33,750 on 28 November 2018.

The largest trade Mark's ever made was exercising 27,007 units of Arbutus Biopharma Corp stock on 16 April 2018 worth over $9,452. On average, Mark trades about 6,501 units every 28 days since 2015. As of 28 November 2018 Mark still owns at least 341,396 units of Arbutus Biopharma Corp stock.

You can see the complete history of Mark Murray stock trades at the bottom of the page.

What's Mark Murray's mailing address?

Mark's mailing address filed with the SEC is C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY, A1, V5J 5J8.

Insiders trading at Arbutus Biopharma Corp

Over the last 10 years, insiders at Arbutus Biopharma Corp have traded over $2,165,982 worth of Arbutus Biopharma Corp stock and bought 1,000 units worth $6,950 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... y Andrew Lo. On average, Arbutus Biopharma Corp executives and independent directors trade stock every 164 days with the average trade being worth of $124,173. The most recent stock trade was executed by Keith S Manchester on 14 August 2024, trading 54,915 units of ABUS stock currently worth $30,752.

What does Arbutus Biopharma Corp do?

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

Complete history of Mark Murray stock trades at Arbutus Biopharma Corp

Arbutus Biopharma Corp executives and stock owners

Arbutus Biopharma Corp executives and other stock owners filed with the SEC include:

• William H. Collier,
  Pres, CEO & Director
• Dr. Michael J. Sofia Ph.D.,
  Chief Scientific Officer
• Dr. Michael J. Sofia,
  Chief Scientific Officer
• Michael J. McElhaugh,
  Chief Bus. Officer
• R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.,
  Sec.
• Lisa M. Caperelli,
  VP of Investor Relations
• R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.C,
  Sec.
• Dr. Gaston Picchio Ph.D.,
  Chief Devel. Officer
• Dr. Elizabeth Howard,
  Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.
• Pam Murphy,
  Investor Relations Consultant
• David C. Hastings,
  CFO & Chief Accounting Officer
• Keith S Manchester,
  Director
• Frank Karbe,
  Director
• Richard C Jr Henriques,
  Director
• Herbert J Conrad,
  Director
• Daniel D Burgess,
  Director
• William T. Symonds,
  Chief Development Officer
• Vivek Ramaswamy,
  Director
• Michael J. Sofia,
  Chief Scientific Officer
• Patrick T. Higgins,
  Chief Business Officer
• Mark Kowalski,
  Sr VP & Chief Medical Officer
• Michael J. Abrams,
  Exec. VP & Chief Discovery Off
• Mark J. Murray,
  President & CEO
• Peter Lutwyche,
  Chief Tech. Operations Officer
• J. Christopher Naftzger,
  General Counsel and CCO
• Karen Sims,
  Chief Medical Officer
• Bruce Cousins,
  Exec VO & CFO
• Associates Gp Llcqvt Fund V...,
  
• Sciences Ltd. Roivant,
  10% owner
• Holdings Ltd.Dexcel Pharma ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Global Investors Lp Viking ...,
  
• Global Performance Llc Viki...,
  
• Patrick Machado,
  
• Koert Vanden Enden,
  Chief Accounting Officer
• Melissa Rewolinski,
  Director
• David C Hastings,
  Chief Financial Officer
• Gaston Picchio,
  Chief Development Officer
• Myrtle S Potter,
  Director
• James R Meyers,
  Director
• Frank Torti,
  Director
• William H. Collier,
  President and CEO
• Global Performance Llc Viki...,
  
• Andrew Cheng,
  Director
• Tram Tran,
  Director
• Elizabeth Howard,
  EVP, GC, Compliance
• Michael J. Mc Elhaugh,
  Interim President & CEO